Abstract
It is well-established that abnormalities in lipoprotein metabolism are associated with an increased risk for atherosclerotic cardiovascular disease (1). Therapeutic strategies designed to reduce circulating lipid levels have also been shown to decrease cardiovascular morbidity and mortality (2, 3). Although these studies have been carried out exclusively in patients with normal renal function, hyperlipidemia is common in patients with renal disease, and the incidence of cardiovascular disease complications is high in this population. Thus, it is important to understand the pathophysiology and treatment of hyperlipidemia in patients with renal disease.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
